13
weights, and full TWAS summary statistics publicly available (https://github.com/ypark/fqtl).
47

III. METHODS
48
A. Factored QTL model specification 49 We propose fQTL, a multi-response, multivariate regression approach to jointly model gene expression across matrix X, which is centered (but not scaled). We fit a linear model: We define Θ jt to be the effect of SNP j on gene expression of that gene in tissue t. We define 54 σ(z) = 1/(1 + exp(−z)) and we set V max = V[y] and V min = 10 −4 V max .
55
The key idea of fQTL is that we assume the eQTL effect size matrix Θ can be decomposed into tissue-invariant 56 components θ snp and tissue-dependent components θ tis :
Here, we assume K = 1 for ease of interpreting the results, although our inference algorithm (described 58 below) supports fitting arbitrary K ≤ m.
59
The fundamental problem in fitting a multivariate regression on genotypes X is co-linearity of the columns 60 of X due to LD. Co-linearity causes ordinary regression to be ill-posed (infinitely many solutions), but a
61
Bayesian regression with the spike and slab prior can successfully solve the variable selection problem 10-15 .
62
Here, we assume the spike and slab (point-normal mixture) prior on each column of θ snp and θ tis . Considering where N(x; ·, ·) denotes the Gaussian density and δ(x) denotes the Dirac delta function (point mass at zero).
65
B. Stochastic variational inference 66
For our model, the spike and slab prior is non-conjugate to the likelihood. Therefore, estimating the posterior 
Our goal is to find the q with minimum KL-divergence with p by optimizing over Ψ; however, in general We instead used stochastic optimization to optimize the variational objective, an approach known as stochastic 84 variational inference (SVI) 21, 22 . The key idea is to perform gradient ascent, taking steps along the natural 85 gradient of the objective function 23 with respect to the variational parameters:
For our choice of approximating family q, the regularizer term above has an analytic form, as previously 87 derived 13 :
Although we can analytically take gradients of the regularizer (not shown), our use of the spike and slab 89 prior means it is not possible to take gradients of E q [ln p(y, | X, θ)]. We use the log-derivative trick to obtain 90 an unbiased estimator for the natural gradients (see Supplementary Methods) 21 :
Naive implementation of SVI is slow to converge because of the variance of the stochastic gradient. for n < p (which is true in our setting). (2) We further reduce the variance of the stochastic gradient 25 .
97
Even with variance reduction techniques, the convergence rate and sparsity of the final fitted model is 98 highly sensitive to the hyperparameters and learning rate. We developed a variational approximation for the 99 hyperparameters (see Supplementary Methods) which allowed us to simultaneously fit the model parameters 100 θ and hyperparameters (π, τ ). We tuned the learning rate on simulated datasets, finding that a fixed value 101 0.01 worked well.
102
C. Factored QTL model inference 103 In order to fit fQTL using SVI, we only need to characterize the distribution of η under the variational 104 approximation, relying on a previously derived result for the variance of the product of two random 107 We simulated multi-tissue gene expression matrices Y using genotypes in 450 individuals from the specified 108 cis-regulatory window around each gene, varying the number of causal eQTLs, the number of tissues of action,
109
and the proportion of variance of gene expression h 2 explained by SNP-specific effects. For each setting, we 110 simulated 175 randomly chosen genes. We matched the number of missing observations in each tissue to the 111 number of missing observations in each GTEx tissue. We then quantile-normalized the generated expression 112 values to match real GTEx expression profiles.
113
We sampled SNP-specific effects θ snp j and tissue-specific effects θ tis t from the standard normal distribution.
114
We then generated gene expression within tissues with non-zero tissue effect (i.e., tissues within which gene 115 expression could also be genetically controlled) using a linear model 17,27 :
116
For tissues with zero tissue effect, we sampled expression values from N (0, V[η t ]).
117
E. Identification of tissues of action in GTEx 118
We obtained individual genotypes and gene-level RNA-seq read counts from the GTEx consortium (version 119 6). We restricted our analysis to coding genes annotated by GENCODE v19 and tissues with sample size 120 n ≥ 50. Within each tissue, we further restricted to genes having read count greater than 10 in at least 121 50% of samples. To convert read counts to logarithmic scale, rlog transformed the data using the DESeq2 122 package 28 . We confirmed after the rlog transformation there was no mean-variance correlation.
123
For GTEx gene expression, significant PVE is attributable to experimental and technical confounding 124 variables. For each tissue, we jointly fit a polygenic QTL model and performed sparse matrix factorization of 125 the residual to identify non-genetic, technical confounders on the 1000 most variable genes in each tissue.
126
We modeled the k-th most variable gene's expression in i-th sample as:
Here, the matrix of genetic effects Θ jk denotes the effect of SNP j on gene k. We fixed Θ jk = 0 if SNP 128 j was not located within the specified cis-regulatory window of gene k. We enforced rank sparsity of the 129 factorization by assuming a group spike and slab prior 18 on U and V (see Supplementary Methods). We 130 defined learned covariates as columns of U with column posterior inclusion probability PIP > 0.5. We 131 included these learned covariates as well as known covariates in subsequent analysis by introducing another 132 linear term in our original model:
To account for correlations between the columns of C, we assume the spike and slab prior on the elements
134
Λ kt , and incorporate the entire matrix into our stochastic variational inference algorithm described above.
135
F. TWAS using factored QTL effects 136 We perform tissue-specific TWAS by defining tissue-specific QTL effects θ t = θ snp θ tis t . Prior work proposed a 137 summary-based TWAS statistic T = z θ t and characterized its null distribution 1 . However, the proposed 138 statistic depends only on a point estimate of θ t , while our factored QTL model estimates both a posterior 139 mean and a posterior variance of θ t .
140
We derive the null distribution of T , accounting for the posterior variance of the estimated effects. As before,
141
we assume the null distribution of GWAS z-scores follows the multivariate Gaussian distribution, z ∼ N (ẑ, R)
142
where the covariance matrix R = X X/n is estimated from the GWAS cohort genotypes (or approximated 143 using a reference cohort). 
Compared to the previously derived null distribution, the null distribution of our TWAS statistic has two 147 additional terms in the variance which additionally penalize the model complexity of the polygenic QTL 148 model. This modified variance leads to a more conservative hypothesis test.
149
We performed summary-based tissue-specific TWAS using our method for Alzheimer's disease and schizophre- 
The key idea of fQTL is to assume the eQTL effect size matrix Θ can be decomposed into tissue-invariant 168 components θ snp and tissue-dependent components θ tis :
In this study, we focus on K = 1 for intuitive interpretation, although our method supports arbitrary K.
170
In this case, the intuition behind the factorization is that the estimated effect of a specific SNP on gene 171 expression in a specific tissue could be explained by several possible mechanisms. (1 across tissues since it is determined solely by sequence, while explanations (2) and (3) can be tissue-specific.
177
By factorizing the matrix of effects Θ, we allow our model to fit both types of effects. As K increases, we 178 posit the existence of different causal eQTLs for different subsets of tissues, but do not explore this possibility 179 in this study.
180
The challenge in fitting polygenic QTL models is that the columns of X are co-linear due to LD, and
181
we need to select a sparse set of relevant predictors using the spike and slab prior 13 . This prior is non- made C++ source code implementing the framework and an R package wrapping the models publicly available
189
(https://github.com/ypark/fqtl).
190
Our analysis pipeline is shown in Fig. 1 
229
We then investigated the power to detect the tissue of action (Fig. 2b) . The results generally agree with those
230
for causal variant identification. However, the number of causal SNPs had less impact on tissue prediction.
231
Multi-tissue fQTL clearly dominated in all settings and gained more power as the number of tissues of action 232 increased.
233
We finally investigated the sensitivity of our method to mis-specification of K. We first simulated scenarios 
240
We then simulated a worst-case scenario for our model with arbitrary K by randomly assigning elements of 241 Θ to be non-zero (Supp. Fig. 9 
255
Across the 48 tissues, 30% of variability is explained by non-genetic factors on average.
256
We found many of the inferred factors are highly correlated with known covariates: tissue ischemic time, age, 257 body mass index, and gender (Supp. Fig. 10 ). However, in our analysis we included both known and learned
258
covariates, again using the spike and slab prior to perform variable selection among the correlated covariates. correlated with the sample size in that tissue (Fig. 3) . However, fQTL increased power to detect active genes 265 over sQTL, finding on average 3.8 times as many active genes across the 48 tissues.
266
We then used the estimated tissue posterior inclusion probability p(θ tis t = 0) to compute a correlation 267 matrix between tissue activity patterns across all genes (Fig. 4) TWAS genes in the GWAS catalog were significantly associated in brain, likely due to limited sample sizes.
287
In comparison, 3 of these 15 genes were found by fQTL in brain tissues (PVRL2, HLA-DRB1, HLA-DRB5). increased permeablility, imbalance of the immune system, and neurodegeneration 47 .
300
We found 382 tissue-specific TWAS genes in SCZ using fQTL (FDR 1%, Fig. 6 genes associated with these diseases.
327
There are a number of modeling and algorithmic improvements which can be made to our approach.
328
Most importantly, in this study we assumed the eQTL-by-tissue effect matrix was rank one for intuitive 329 interpretation: we fit a model with one vector of SNP-specific effects and one vector of tissue-specific effects.
330
Our simulation revealed that mis-specification of this parameter leads to slight loss of power in our model.
331
However, the problem of finding the optimal k requires some attention. We could determine k through 
334
We motivated our study of the rank one model by suggesting that the tissue-specific effect sizes of eQTLs 335 observed in single-tissue approaches could be decomposed into tissue-invariant and tissue-specific components.
336
In particular, we suggested that the tissue-specific component could be explained by variation across tissues 337 in epigenomic state, or by altered expression of the upstream regulator in specific tissues. Distinguishing 338 these two cases is necessary to interpret the mechanism of cis-regulation for genes identified by downstream
339
TWAS and translate TWAS genes into therapeutics. However, the model we have proposed here cannot yet 340 distinguish between these two cases. Future work should incorporate epigenomic information, transcription 341 factor binding, and transcription factor expression to make specific testable biological predictions regarding 342 transcriptional regulation of TWAS genes.
343
In this study, we assumed gene expression was Gaussian, and coerced the GTEx expression data to be 344 approximately Gaussian. However, a more principled approach would be to use a more appropriate distribution
345
(such as the negative binomial distribution) to directly model the process which generated the observed read 346 counts. Existing methods cannot be easily extended to implement this approach because they make strong 347 assumptions (like Gaussianity) and implement model-specific inference algorithms. Our SVI framework makes 348 implementing extensions of this sort straightforward, without modification of the core inference algorithm.
349
Future work should estimate the improvements in statistical power and false discovery rate when analyzing 350 diverse data types in their observed, un-transformed distribution.
351
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We thank Alexander Gusev, Benjamin Iriarte, Alkes Price, and Luke Ward for helpful discussions. BLOC1S2  SPATA7  MYRFL  CHMP7  PRSS36  CDK10  ULBP2  ULBP1  ICAM3  BPHL  TMEM158  RSBN1L  BCAM  APOLD1  CD34  CLDN5  ZNF180  GK5  SGTA  SERPINH1  PVRL2  S100A9  HECA  PSMA7  AACS  PRKD2  CRTC3  FOCAD  TBC1D3F Recall we assume the spike and slab prior on the parameter θ, and seek to find the optimal q(θ) to approximate 371 the intractable posterior p(θ | X, Y, ·). Under the variational approximation:
In order to find the optimal q, we need to optimize the evidence lower bound, which requires estimating a 373 stochastic gradient using the log-derivative trick 21 : directly and speed up the inference, we re-parameterize:
Now, we sample (s) ∼ N (0, I), re-parameterize again to get a differentiable term 61 η (s) = µ + s √ ν, and 379 take gradients with respect to µ, v:
and with respect to α, β, γ:
382
We can write the gradients using the chain rule, and efficiently compute them in parallel using matrix 383 operations. For every stochastic vector (s) we can evaluate log-likelihood vector f s , where
384
First we can take derivatives with respect to
and with respect to
Applying the chain rule:
B. Matrix factorization 388
For matrix factorization H = U V we used group spike-slab prior 18 :
Under the variational approximation we define
We use the same prior distribution and variational approximation for v k vectors.
391
We can characterize
and log-likelihood
and estimate stochastic components of gradients:
Using G 1 and G 2 we can derive gradient matrices straightforwardly
On these partial gradients we applying chain rules with respect to the original variational parameters.
397
C. Control variate 398
Consider a generic variational approximation problem with surrogate distribution q(θ | λ) for the intractable 399 distribution f (θ). We want to calculate the gradient with respect to the variational parameter λ:
gradient is equal to:
We can the find optimal ξ * by solving:
Previous work 21 derived the optimal ξ:
Here, we define g(θ) = ∇ λ ln q(θ | λ). Then, we have:
However, accurately estimating ξ * requires many samples
resulting in a stochastic gradient estimator with variance:
2 ).
D. Hyperparameter tuning 411
The spike and slab prior is defined by two hyperparameters, the prior inclusion probability π and prior effect 412 size precision τ . In our extensive simulation experiments, direct optimization over the hyperparameters 413 leads to degenerate solutions. To circumvent degeneracy, previous work used importance sampling or grid 414 search 13,38 .
415
Here, we included the hyperparameters in the variational surrogate distribution. We re-parameterized:
In our SVI updates, we updated δ 0 and δ j simultaneously. Similarly, for the prior precision τ and variational
418
precision γ j :
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